Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$9.55 - $19.0 $120,330 - $239,400
-12,600 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$16.79 - $20.88 $211,554 - $263,088
12,600 New
12,600 $233,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $805M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Cannon Global Investment Management, LLC Portfolio

Follow Cannon Global Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cannon Global Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cannon Global Investment Management, LLC with notifications on news.